newsfilter
← Latest News
GlobeNewswire·

Alaunos Therapeutics Reports Second Quarter 2022 Financial Results

Advancing TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications; plan to present early data in 3Q 2022 at a scientific conference; moving ahead with second dose level Extended Cooperative Research and